NCT07347041 Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Hip Osteoarthritis(OA)
| NCT ID | NCT07347041 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Tiantan Hospital |
| Condition | Myofascial Trigger Points |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,036 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,036 participants in total. It began in 2025-12-01 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Chronic musculoskeletal pain (CMP) is a common disease in China, with a high incidence among the elderly, and has a significant impact on patients' quality of life. Hip osteoarthritis is a common type of CMP. Currently, both domestic and international studies have confirmed that glucocorticoid injection at myofascial trigger points(MTrPs) can alleviate patients' pain symptoms. MTrPs injection is safe and easy to operate, and can improve the clinical management efficiency of patients with knee osteoarthritis. Therefore, we designed a prospective, randomized controlled, blinded outcome, non-inferiority study to compare the long-term clinical efficacy of glucocorticoid injection at myofascial trigger points and complex intra-articular injection in treating hip osteoarthritis. Patients will be randomly divided into two groups and receive either glucocorticoid injection at MTrPs or joint cavities. After treatment, patients will be followed up for 2 years. Their NRS scores, WOMAC scores, Patient Global Impression of Change(PGIC) scale, and adverse reactions will be recorded at 2 weeks, 4 weeks, 8 weeks, 12 weeks, and 24 weeks. If the results indicate that the clinical efficacy of myofascial trigger point injection for knee osteoarthritis is not inferior to that of injection at intra-articular injection, it will provide a safe and simple treatment option that is easy to promote for patients who do not respond to conservative treatment.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of hip osteoarthritis with radiographic evidence of osteoarthritis (Kellgren-Lawrence grade 1-4) confirmed by at least two orthopedic surgeons, pain specialists, or general practitioners, with physical examination confirming at least one myofascial trigger point; * Disease duration exceeding 3 months; * Age ≥ 45 years; * Numerical Rating Scale (NRS) score ≥ 3 points despite prior conservative pharmacological treatment; * Signed informed consent form. Exclusion Criteria: * History of allergy to trial medications such as corticosteroids; * Alcohol abuse; long-term use of opioids (exceeding 2 weeks or more than 3 days per week for over 1 month); suspected use of sedative or analgesic medications; patients on long-term steroid therapy; * Severe neurological disorders, significant hepatic or renal dysfunction, heart failure, coagulation abnormalities, gastric ulcer, diabetes, inflammatory rheumatic diseases, etc.; * Intra-articular injection within the past 6 months or planned joint replacement surgery; * Inability to use pain assessment scales; * Presence of local or systemic infection; * Pregnant or lactating patients.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07347041 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, studying Myofascial Trigger Points. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07347041 currently recruiting?
Yes, NCT07347041 is actively recruiting participants. Contact the research team at 13611326978@163.com for enrollment information.
Where is the NCT07347041 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07347041 clinical trial?
NCT07347041 is sponsored by Beijing Tiantan Hospital. The trial plans to enroll 1,036 participants.